Join
Live feed
·
PRReleasevia Quantisnow
PhaseBio Pharmaceuticals Inc. logo

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding

ByQuantisnow·Wall Street's wire, on your screen.
PHAS· PhaseBio Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PHAS (PhaseBio Pharmaceuticals Inc.) and more on Quantisnow.